- \n
- Four oral sessions to be presented, including validation data for Shield MCD test, selected for highly anticipated NCI Vanguard Study<\/i><\/li>\n
- 18 total abstracts to showcase significant developments in multiomic profiling with liquid and tissue biopsies across screening, recurrence monitoring and treatment selection<\/i><\/li>\n<\/ul>\n
PALO ALTO, Calif.–(BUSINESS WIRE<\/a>)–
\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity\u2122 smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25-30 in Chicago.\n<\/p>\n\nKey data that will be highlighted include:\n<\/p>\n
- \n
- \nAn oral presentation of performance data for the Shield\u2122 MCD test, selected for the National Cancer Institute\u2019s Vanguard Study<\/a> evaluating emerging multi-cancer detection (MCD) technology\n<\/li>\n
- \nAdditional oral presentations on methylation-based cancer signal of origin identification, methylation profiling for lung cancer subtyping, and a real-world data analysis of BRAF mutations in non-small cell lung cancer\n<\/li>\n
- \nAnalytical validation of Guardant\u2019s new tissue profiling assay with integrated multiomics, showing a high success rate with minimal tissue input and supporting the acceleration of novel biomarker discovery\n<\/li>\n
- \nNew methylation-based applications for liquid biopsy, including molecular subtyping of lung and breast cancer, rule-out of actionable genomic mutations, and identification of promoter methylation and MTAP deletions\n<\/li>\n<\/ul>\n
\n\u201cWe look forward to sharing new data demonstrating the tremendous potential of the Guardant Infinity smart liquid biopsy platform to provide researchers and healthcare providers with a more complete picture of cancer, including genomics, epigenomics and more,\u201d said Helmy Eltoukhy, Guardant Health chairman and co-CEO. \u201cThis multidimensional view of cancer biology is enabling advances in precision oncology ranging from blood-based multi-cancer detection to identification of novel biomarkers that can help bring the next generation of cancer therapeutics to patients sooner.\u201d\n<\/p>\n
\nThe full abstracts for Guardant Health and a list of all abstracts being presented at AACR 2025 can be found on the AACR website<\/a>.\n<\/p>\n
\nFor information and updates from the conference, follow Guardant Health on LinkedIn<\/a>, X (Twitter)<\/a> and Facebook<\/a> or visit AACR booth #1523.\n<\/p>\n
\n
\n \n Full List of Guardant Health Presentations<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n Date and Time (CDT)<\/b><\/p>\n<\/td>\n
\n Title<\/b><\/p>\n<\/td>\n
\n Abstract and Poster Section\/Board<\/b><\/p>\n<\/td>\n
\n Guardant Product<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n Multi-Cancer<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \nSunday, April 27, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nAnalytical validation of a tissue-free epigenomic assay for circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in early-stage cancer\n<\/p>\n<\/td>\n
\n \nAbstract #692\n<\/p>\n
\nPoster Section 29 Poster Board #25\n<\/p>\n<\/td>\n
\n \nGuardant Reveal\u2122\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nSunday, April 27, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nDevelopment and characterization of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA\n<\/p>\n<\/td>\n
\n \nAbstract #733\n<\/p>\n
\nPoster Section 31 Poster Board #18\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nSunday, April 27, 3:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nA novel methylation-based classifier to identify cancer signal of origin using blood-based testing\n<\/p>\n<\/td>\n
\n \nOral Minisymposium Session\n<\/p>\n
\nAbstract #6365\n<\/p>\n<\/td>\n
\n \nGuardant Infinity Screening\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nMonday, April 28, 9:00am-12:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nInferring immune and tissue cell type contributions to cell-free DNA (cfDNA) with a DNA methylation assay\n<\/p>\n<\/td>\n
\n \nAbstract #1951\n<\/p>\n
\nPoster Section 28\n<\/p>\n
\nPoster Board #19\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nMonday, April 28, 9:00am-12:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nDetection of clinically actionable somatic variants in post-operative samples from patients with molecular residual disease\n<\/p>\n<\/td>\n
\n \nAbstract #1953\n<\/p>\n
\nPoster Section 28\n<\/p>\n
\nPoster Board #21\n<\/p>\n<\/td>\n
\n \nGuardant Reveal\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nMonday, April 28, 9:00am-12:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nBlood-based mapping of the personalized tumor epigenomic landscape\n<\/p>\n<\/td>\n
\n \nAbstract #1955\n<\/p>\n
\nPoster Section 28 Poster Board #23\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nMonday, April 28, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nAnalytical validation of cancer gene promoter methylation detection in cfDNA liquid biopsy assay\n<\/p>\n<\/td>\n
\n \nAbstract #3255\n<\/p>\n
\nPoster Section 29 Poster Board #20\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTuesday, April 29, 2:30-4:30pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nEvaluation of a plasma cell-free DNA methylation-based multi-cancer detection test\n<\/p>\n<\/td>\n
\n \nOral Minisymposium\n<\/p>\n
\nSession\n<\/p>\n
\nAbstract #6425\n<\/p>\n<\/td>\n
\n \nShield MCD Test\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTuesday, April 29, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nA tumor-specific, methylation-based algorithm to identify MTAP gene deletions via tissue-free circulating tumor DNA\n<\/p>\n<\/td>\n
\n \nAbstract #5924\n<\/p>\n
\nPoster Section 30 Poster Board #16\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTuesday, April 29, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nAnalytical validation of a robust, integrated multiomics tissue assay powered by the Guardant Infinity platform\n<\/p>\n<\/td>\n
\n \nAbstract #5935\n<\/p>\n
\nPoster Section 30 Poster Board #27\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTuesday, April 29, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nLandscape of epigenomic tumor fraction in large pan-cancer cfDNA cohort\n<\/p>\n<\/td>\n
\n \nAbstract #5936\n<\/p>\n
\nPoster Section 30 Poster Board #28\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nWednesday, April 30, 9:00am-12:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nAnalytical validation of a new plasma-only bioinformatics classifier to identify variants from clonal hematopoiesis (CH) in cfDNA liquid biopsy assays\n<\/p>\n<\/td>\n
\n \nAbstract #6603\n<\/p>\n
\nPoster Section 9 Poster Board #10\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n Lung<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \nSunday, April 27, 3:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nNon-invasive cell free DNA (cfDNA) methylation profiling for accurate proportional quantification of lung cancer subtypes\n<\/p>\n<\/td>\n
\n \nOral Minisymposium\n<\/p>\n
\nSession\n<\/p>\n
\nAbstract #1142\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTuesday, April 29, 9:00am-12:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nEGFR PACC mutations occur more frequently as compound mutations with better responses to EGFR TKIs\n<\/p>\n<\/td>\n
\n \nAbstract #4594\n<\/p>\n
\nPoster Section 30 Poster Board #14\n<\/p>\n<\/td>\n
\n \nGuardant360\u00ae\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTuesday, April 29, 2:30-4:30pm\n<\/p>\n
\n\u00a0\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nUnveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLC\n<\/p>\n<\/td>\n
\n \nOral Minisymposium Session\n<\/p>\n
\nAbstract #6389\n<\/p>\n<\/td>\n
\n \nGuardant Inform\u2122\n<\/p>\n<\/td>\n<\/tr>\n
\n \n Breast<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \nMonday, April 28, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nPre- and post-operative analysis of circulating tumor DNA in patients with breast cancer treated with neoadjuvant therapy using a tissue-free, methylation-based approach\n<\/p>\n<\/td>\n
\n \nAbstract #3360\n<\/p>\n
\nPoster Section 32 Poster Board #30\n<\/p>\n<\/td>\n
\n \nGuardant Reveal\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \nMonday, April 28, 2:00-5:00pm\n<\/p>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n \nLiquid based methylation profiling for quantification of breast cancer subtypes\n<\/p>\n<\/td>\n
\n \nAbstract #3247\n<\/p>\n
\nPoster Section 29 Poster Board #12\n<\/p>\n<\/td>\n
\n \nGuardant Infinity\n<\/p>\n<\/td>\n<\/tr>\n
\n \n Colorectal<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \nMonday, April 28, 9:00am-12:00pm\n<\/p>\n<\/td>\n
\n \nEmploying joint modeling to support clinical interpretation of ctDNA dynamics during the treatment of advanced colorectal cancer\n<\/p>\n<\/td>\n
\n \nAbstract #2481\n<\/p>\n
\nPoster Section 41 Poster Board #2\n<\/p>\n<\/td>\n
\n \nGuardant Inform\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
About Guardant Health<\/b><\/p>\n
\nGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn<\/a>, X (Twitter)<\/a> and Facebook<\/a>.\n<\/p>\n
Forward-Looking Statements<\/b><\/p>\n
\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250422372352\/en\/<\/a><\/span><\/p>\n
Investor Contact:
\n<\/b>
Zarak Khurshid
\n
investors@guardanthealth.com<\/a><\/p>\nMedia Contact:
\n<\/b>
Michael Weist
\n
press@guardanthealth.com
\n<\/a>
+1 317-371-0035\n<\/p>\nKEYWORDS:<\/b> United States North America California Illinois<\/p>\n
INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Oncology General Health Health Hospitals Health Technology Clinical Trials<\/p>\n
- 18 total abstracts to showcase significant developments in multiomic profiling with liquid and tissue biopsies across screening, recurrence monitoring and treatment selection<\/i><\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250422372352\/en\/1330243\/3\/GuardantHealthLogo_TM_RGB-2C.jpg\")
<\/td>\n<\/tr>\n